Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Letters to the Editor

When Should Nitroglycerine Be Avoided in Hypertensive Encephalopathy?

Mohamed A. Sheta, Madhu Paladugu, Joshua Mendelson, Neil R. Holland
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.111.175703
Hypertension. 2011;58:e187-e188
Originally published October 19, 2011
Mohamed A. Sheta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madhu Paladugu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Mendelson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil R. Holland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

To the Editor:

Intravenous nitroglycerin is a well-recognized treatment of acute hypertension and hypertensive encephalopathy.1 We are reporting a patient presented with posterior reversible encephalopathy syndrome (PRES) secondary to hypertensive crisis who deteriorated when his blood pressure was treated with intravenous nitroglycerin. We, therefore, suggest that nitroglycerine should be discontinued in all patients with hypertensive encephalopathy with worsening neurological status or in the presence of typical radiological findings.

A 63-year–old man with a history of hypertension and diabetes mellitus presented with a severe headache, associated with nausea and vomiting. He had a history of alcohol abuse complicated by liver cirrhosis but denies drinking for many years. His medications include insulin glargine, atenolol 50 mg, gabapentin, zolpidem, and tamsulosin. His blood pressure was 222/110 mm Hg, and his pulse rate was 68 bpm. Neurological examination revealed mild disorientation but no papilledema or focal neurological deficit. Abnormal laboratory studies on admission included blood glucose 382 mg/dL, alanine transaminase 55 U/L, and aspartate aminotransferase 43 U/L. Toxicology screen was positive for benzodiazepines. Urinalysis revealed proteinuria and glycosuria. A brain computed tomography scan showed hypodensities in the white matter of posterior parietal lobes bilaterally (Figure 1A and 1B). He was started on intravenous labetalol but then became bradycardic, so an intravenous nitroglycerin drip was initiated. His medications stopped temporally because of the nausea and vomiting, and insulin drip was initiated for proper glycemic control. The next day, the blood pressure was 180/100 mm Hg, the heart rate was 90 bpm, and blood sugar was 206 mg/dL, but the conscious level deteriorated, and he started to report visual loss. A follow-up computed tomography scan of the head showed worsening of the initial findings (Figure 2A and 2B). Brain MRI showed abnormal signal on the fluid-attenuated inversion recovery and T2-weighted images involving the occipital lobes with extension to parietal and frontal lobes bilaterally (Figure 3A and 3B). Diffusion-weighted images showed no areas of restriction, excluding infarction, and confirming the diagnosis of PRES. Intravenous nitroglycerin was stopped. We decided to restart the intravenous labetalol drip because his heart rate was 90 bpm. After 12 hours of labetalol infusion, his blood pressure was 145/80 mm Hg, and his conscious level gradually improved. He was fully conscious and coherent the following day. We assumed that the clinical and radiological deterioration was secondary to the intravenous nitroglycerine, because, in spite of gradual lowering of the blood pressure, his neurological deficit became markedly worse. Also, the patient improved when nitroglycerine was replaced.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

CT scan of the head without contrast before nitroglycerine.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

CT scan of the head without contrast after nitroglycerine.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

MRI FLAIR images of the brain after nitroglycerine.

The term “hypertensive encephalopathy” was first used in 1928 to indicate the concept of transient neurological dysfunction precipitated by malignant hypertension.2 Symptoms typically start 12 to 48 hours after a sudden and sustained increase in blood pressure and include severe headache, vomiting, confusion, seizures, visual changes, and, in untreated cases stupor, and coma.3 Treatment consists of acute blood pressure control using intravenous medications, including nitroglycerine, and patients who are promptly treated usually recover without deficit.1

PRES was first reported in 1996 in a series of acutely ill patients admitted for reversible neurological symptoms with abnormal and also reversible brain imaging,4 and, despite 15 years of increasing attention, the pathophysiology is still not entirely understood. The most popular hypothesis is that PRES is related to a cerebral hyperperfusion state, with breakdown of the blood-brain barrier, and extravasation of fluid, which is potentially containing blood or macromolecules, resulting in cortical and subcortical edema.5–7 However, some patients have demonstrable vasoconstriction on radiological imaging8,9 and perfusion deficits in radionuclide studies10,11 that may be explained by disordered cerebral autoregulation, leading to reactive focal vasoconstriction.12–14 Finally, compression of the microcirculation from the mass effect of vasogenic edema may play a role.

The most common presenting symptoms include severe headache, confusion, visual symptoms, and seizures. Common triggers include acute hypertension and the administration of cyclosporine and tacrolimus. Less commonly reported triggers are cocaine and methamphetamine abuse, cancer chemotherapy, systemic lupus erythematosus, chronic renal failure, and hemolytic uremic syndrome. Chronic hypertension alters the structure of cerebral blood vessels through atherosclerosis, lipohyalinosis, hypertrophy, remodeling, stiffening, alterations in resting cerebral blood flow, and endothelial dysfunction. It also disrupts vasoregulatory mechanisms that assure an adequate blood supply to the brain.15 Apart from hypertrophy and remodeling, these vascular changes are injurious and may make the brain tissue more susceptible to PRES.

The regions of the brain most commonly involved in imaging studies are the parieto-occipital and temporal lobes. It is not entirely known why PRES favors the posterior circulation, but this may arise from a relative lack of sympathetic innervation at the level of the arterioles supplied by the vertebrobasilar system compared with the anterior circulation.7,16–18 Clinical recovery usually occurs within 1 to 53 days, with 25% of patients recovering within 1 day. Recurrence is infrequent, although triggering factors for PRES have repeatedly been experienced by some patients.19

Perspectives

Our patient presented with hypertensive encephalopathy and a computed tomography scan of the head that suggested PRES. His neurological deficit became markedly worse, both clinically and radiographically, when we treated him with intravenous nitroglycerin, but then improved when this medication was replaced. Nitroglycerin dilates cerebral arteries and alters both the global and regional cerebral blood flow, which may augment the autoregulation failure. This adverse effect of nitroglycerine in PRES has been reported previously in the form of 2 case reports.20,21 However, nitroglycerin remains an established treatment for hypertensive encephalopathy. Furthermore, the distinction between hypertensive encephalopathy and hypertensive PRES may be artificial and would appear to rest primarily on the presence or absence of radiographic findings, which may be subtle and could be missed on the computed tomography scan. In other words, the diagnosis of PRES may not be immediately obvious in a patient presenting with hypertensive encephalopathy, particularly if brain imaging is not immediately available. We would, therefore, recommend using nitroglycerin with caution. Also, we recommend immediate discontinuation of intravenous nitroglycerine in the presence of worsening neurological status or typical radiological findings. Alternate parenteral blood pressure–lowering agents include labetalol, enalapril, and nicardipine.

Mohamed A. Sheta
Madhu Paladugu
Department of Medicine
Monmouth Medical Center
Long Branch, NJ

Joshua Mendelson
Neil R. Holland
Department of Medicine
Monmouth Medical Center
Long Branch, NJ
Neurology Specialists of Monmouth County
West Long Branch, NJ
Department of Neurology
Drexel University College of Medicine
Philadelphia, PA

Disclosures

None.

Footnotes

  • Letters to the Editor will be published, if suitable, as space permits. They should not exceed 1000 words (typed double-spaced) in length and may be subject to editing or abridgment.

  • © 2011 American Heart Association, Inc.

References

  1. 1.↵
    1. Vidt DG
    . Current concepts in treatment of hypertensive emergencies. Am Heart J. 1986;111:220–225.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Oppenheimer BS,
    2. Fishberg AM
    . Hypertensive encephalopathy. Arch Int Med. 1928;41:264–278.
    OpenUrlCrossRef
  3. 3.↵
    1. Clarke E,
    2. Murphy EA
    . Neurological manifestations of malignant hypertension. BMJ. 1956;2:1319–1326.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Hinchey J,
    2. Chaves C,
    3. Appignani B,
    4. Breen J,
    5. Pao L,
    6. Wang A,
    7. Pessin MS,
    8. Lamy C,
    9. Mas JL,
    10. Caplan LR
    . A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Johansson B
    . The blood–brain barrier and cerebral blood flow in acute hypertension. Acta Med Scand. 1983;678(suppl):107–112.
    OpenUrl
  6. 6.↵
    1. Tamaki K,
    2. Sadoshima S,
    3. Baumbach GL,
    4. Iadecola C,
    5. Reis DJ,
    6. Heistad DD
    . Evidence that disruption of the blood–brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy. Hypertension. 1984;6:75–81.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. MacKenzie ET,
    2. Strandgaard S,
    3. Graham DI,
    4. Jones JV,
    5. Harper AM,
    6. Farrar JK
    . Effects of acutely induced hypertension in cats on pial arteriolar caliber, local cerebral blood flow, and the blood–brain barrier. Circ Res. 1976;39:33–41.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Stott VL,
    2. Hurrell MA,
    3. Anderson TJ
    . Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35:83–90.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Lewis LK,
    2. Hinshaw DB Jr.,
    3. Will AD,
    4. Hasso AN,
    5. Thompson JR
    . CT and angiographic correlation of severe neurological disease in toxemia of pregnancy. Neuroradiology. 1988;30:59–64.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Naidu K,
    2. Moodley J,
    3. Corr P,
    4. Hoffmann M
    . Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia. Br J Obstet Gynaecol. 1997;104:1165–1172.
    OpenUrlPubMed
  11. 11.↵
    1. Tajima Y,
    2. Isonishi K,
    3. Kashiwaba T,
    4. Tashiro K
    . Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography. Intern Med. 1999;38:4–5.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Ay H,
    2. Buonanno FS,
    3. Schaefer PW,
    4. Le DA,
    5. Wang B,
    6. Gonzalez RG,
    7. Koroshetz WJ
    . Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998;51:1369–1376.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Koch S,
    2. Rabinstein A,
    3. Falcone S,
    4. Forteza A
    . Diffusion-weighted imaging shows cytotoxic and vasogenic edema in eclampsia. AJNR Am J Neuroradiol. 2001;22:1068–1070.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Mukherjee P,
    2. McKinstry RC
    . Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology. 2001;219:756–765.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Iadecola C,
    2. Davisson RL
    . Hypertension and cerebrovascular dysfunction. Cell Metab. 2008;7:476–484.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Edvinsson L,
    2. Owman C,
    3. Sjoberg NO
    . Autonomic nerves, mast cells, and amine receptors in human brain vessels: histochemical and pharmacologicstudy. Brain Res. 1976;115:377–393.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Beausang-Linder M,
    2. Bill A
    . Cerebral circulation in acute arterial hypertension: protective effects of sympathetic nervous activity. Acta Physiol Scand. 1981;111:193–199.
    OpenUrlPubMed
  18. 18.↵
    1. Roth C,
    2. Ferbert A
    . Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psych. 2010;81:773–777.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Finsterer J,
    2. Schlager T,
    3. Kopsa W,
    4. Wild E
    . Nitroglycerin-aggravated pre-eclamptic posterior reversible encephalopathy syndrome (PRES). Neurology. 2003;61:715–716.
    OpenUrlFREE Full Text
  20. 20.↵
    Edvinsson and MacKenzie. Amine mechanisms in the cerebral circulation. Pharmacol Rev. 1976;28:275–348.
    OpenUrlPubMed
  21. 21.↵
    1. Kühn AL,
    2. Huch N,
    3. Wendt G,
    4. Dooms G,
    5. Droste DW
    . First description of posterior reversible encephalopathy syndrome as a complication of glycerolnitrate patch following open cardiac surgery. Acta Neurol Scand. 2011;124:218–220.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
November 2011, Volume 58, Issue 5
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    When Should Nitroglycerine Be Avoided in Hypertensive Encephalopathy?
    Mohamed A. Sheta, Madhu Paladugu, Joshua Mendelson and Neil R. Holland
    Hypertension. 2011;58:e187-e188, originally published October 19, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.111.175703

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    When Should Nitroglycerine Be Avoided in Hypertensive Encephalopathy?
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    When Should Nitroglycerine Be Avoided in Hypertensive Encephalopathy?
    Mohamed A. Sheta, Madhu Paladugu, Joshua Mendelson and Neil R. Holland
    Hypertension. 2011;58:e187-e188, originally published October 19, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.111.175703
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Stroke
    • Cerebrovascular Disease/Stroke

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured